InMed Pharmaceuticals (INM) Stock Chart & Stock Price History $2.32 -0.03 (-1.07%) As of 09:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock InMed Pharmaceuticals Stock Price Performance The InMed Pharmaceuticals (INM) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 19.62%, with a year-to-date return of -51.16%. In the past month, the stock has decreased 16.73%, reflecting recent market activity. As of the latest close, InMed Pharmaceuticals traded at $2.34 with a market cap of $4.69 million and volume of 96,814 shares. Receive INM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+3.35%1 Month Performance-16.73%3 Month Performance-21.26%Year-To-Date Performance-51.16%1 Year Performance-19.62% INM Stock Chart for Friday, August, 15, 2025 INM Chart by TradingView InMed Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/14/2025$2.25$2.34+4.00%$2.40$2.2796,814 shs$4.69 million08/13/2025$2.21$2.25+1.81%$2.26$2.2045,185 shs$4.50 million08/12/2025$2.25$2.21-1.78%$2.27$2.1665,436 shs$4.42 million08/11/2025$2.24$2.25+0.45%$2.30$2.1970,579 shs$4.50 million08/08/2025$2.24$2.24$2.24$2.2013,091 shs$4.48 million08/07/2025$2.27$2.24-1.32%$2.28$2.2027,051 shs$4.48 million08/06/2025$2.31$2.27-1.73%$2.36$2.2396,101 shs$4.54 million08/05/2025$2.37$2.31-2.53%$2.36$2.3046,668 shs$4.62 million08/04/2025$2.39$2.37-0.84%$2.39$2.3249,119 shs$4.75 million08/01/2025$2.43$2.39-1.65%$2.41$2.3150,579 shs$4.79 million Get the Latest News and Ratings for INM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 07/31/2025$2.52$2.43-3.57%$2.56$2.3982,926 shs$4.86 million07/30/2025$2.67$2.52-5.62%$2.61$2.4862,762 shs$5.04 million07/29/2025$2.64$2.67+1.14%$2.70$2.54160,871 shs$5.35 million07/28/2025$2.64$2.64$2.71$2.6269,072 shs$5.28 million07/25/2025$2.68$2.64-1.49%$2.70$2.6139,786 shs$5.28 million07/24/2025$2.69$2.68-0.37%$2.75$2.6339,709 shs$5.36 million07/23/2025$2.65$2.69+1.51%$2.74$2.67111,391 shs$5.39 million07/22/2025$2.63$2.65+0.76%$2.70$2.56119,365 shs$5.30 million07/21/2025$2.67$2.63-1.50%$2.70$2.6161,497 shs$5.26 million07/18/2025$2.63$2.67+1.52%$2.69$2.6553,329 shs$3.23 million07/17/2025$2.62$2.63+0.38%$2.72$2.6074,331 shs$3.18 million07/16/2025$2.78$2.62-5.76%$2.77$2.6095,504 shs$3.36 million07/15/2025$3.17$2.78-12.30%$3.00$2.72191,268 shs$3.36 million07/14/2025$2.75$3.17+15.27%$3.28$2.701.33 million shs$3.84 million Related Companies IMNN Stock Price Chart NRSN Stock Price Chart TRIB Stock Price Chart MTEX Stock Price Chart LPCN Stock Price Chart LEXX Stock Price Chart SYBX Stock Price Chart MTVA Stock Price Chart PRPH Stock Price Chart LSB Stock Price Chart Receive INM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:INM) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access